CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women.
暂无分享,去创建一个
Å. Borg | H. Jernström | M. Henningson | U. Johansson | H. Olsson | Hampus Olsson | Ulla Johansson | Åke Borg
[1] T. Key,et al. Blood concentrations of estradiol and sex hormone-binding globulin in relation to age at menarche in premenopausal British and Japanese women , 1991, Breast Cancer Research and Treatment.
[2] N. Dalay,et al. Are CYP17 genotypes a biomarker for ovarian cancer in patients with cancer history in their family? , 2006, Oncology research.
[3] Å. Borg,et al. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. , 2005, European journal of cancer.
[4] J. Little,et al. CYP17 and breast cancer: no overall effect, but what about interactions? , 2005, Breast Cancer Research.
[5] P. Hall,et al. CYP17 gene polymorphism in relation to breast cancer risk: a case-control study , 2005, Breast Cancer Research.
[6] H. Feigelson,et al. CYP17 genotype predicts serum hormone levels among pre-menopausal women. , 2005, Human reproduction.
[7] J. Chang-Claude,et al. Anthropometric factors and the risk of premenopausal breast cancer in Germany , 2005, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[8] L. Le Marchand,et al. Association of Genetic Polymorphisms with Serum Estrogens Measured Multiple Times During a 2-Year Period in Premenopausal Women , 2005, Cancer Epidemiology Biomarkers & Prevention.
[9] W. Willett,et al. Menstrual Cycle Characteristics and Incidence of Premenopausal Breast Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.
[10] D. Grobbee,et al. Cyp17, Urinary Sex Steroid Levels and Breast Cancer Risk in Postmenopausal Women , 2005, Cancer Epidemiology Biomarkers & Prevention.
[11] D. Gertig,et al. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study , 2005, Breast Cancer Research.
[12] J. Chang-Claude,et al. CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case–control study , 2005, Breast Cancer Research.
[13] M. Lacroix,et al. The “portrait” of hereditary breast cancer , 2005, Breast Cancer Research and Treatment.
[14] T. Key,et al. No association of polymorphisms in CYP17, CYP19, and HSD17-B1 with plasma estradiol concentrations in 1,090 British women. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[15] W. Foulkes,et al. BRCA1 and BRCA2: 1994 and beyond , 2004, Nature Reviews Cancer.
[16] A. Hirvonen,et al. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. , 2003, Mutation research.
[17] G. Giles,et al. Regressive logistic and proportional hazards disease models for within‐family analyses of measured genotypes, with application to a CYP17 polymorphism and breast cancer , 2003, Genetic epidemiology.
[18] E. Bowman,et al. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors , 2003, Breast Cancer Research.
[19] M. García-Closas,et al. Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre‐menopausal women , 2002, International journal of cancer.
[20] H. Adami,et al. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[21] J. Parry,et al. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. , 2002, Mutagenesis.
[22] S. Narod,et al. CYP gene polymorphisms and early menarche. , 2001, Molecular genetics and metabolism.
[23] Å. Borg,et al. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. , 2001, Journal of the National Cancer Institute.
[24] S. Narod,et al. Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. , 2001, Journal of the National Cancer Institute.
[25] N. Chobanyan. Re: Henderson,B.E. and Feigelson,H.S. (2000) hormonal carcinogenesis. Carcinogenesis, 21, 427-433. , 2001, Carcinogenesis.
[26] V. Kosma,et al. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[27] G. Giles,et al. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. , 2000, Journal of the National Cancer Institute.
[28] James D. Yager,et al. Chapter 3: Endogenous Estrogens as Carcinogens Through Metabolic Activation , 2000 .
[29] K McPherson,et al. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. , 2000, BMJ.
[30] J. Yager,et al. Endogenous estrogens as carcinogens through metabolic activation. , 2000, Journal of the National Cancer Institute. Monographs.
[31] M. Gentile,et al. Association between CYP17 gene polymorphism and risk of breast cancer in young women , 1999, International journal of cancer.
[32] P. Lønning,et al. CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. , 1999, Cancer research.
[33] W. Willett,et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. , 1999, Cancer research.
[34] D. Bell,et al. Association between CYP17 polymorphisms and the development of breast cancer. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[35] P. Pharoah,et al. Absolute risk of breast cancer in women at increased risk: a more useful clinical measure than relative risk? , 1998 .
[36] B. Ponder,et al. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. , 1998, British Journal of Cancer.
[37] M. Pike,et al. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. , 1998, Cancer research.
[38] N. Day,et al. Family history and the risk of breast cancer: A systematic review and meta‐analysis , 1997, International journal of cancer.
[39] G. Coetzee,et al. A polymorphism in the CYP17 gene increases the risk of breast cancer. , 1997, Cancer research.
[40] Julian Peto,et al. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies , 1996, The Lancet.
[41] C. Weinberg,et al. Menstrual cycle patterns and risk of breast cancer. , 1994, American journal of epidemiology.
[42] J. Daling,et al. Risk factors for breast cancer in younger women. , 1994, Journal of the National Cancer Institute. Monographs.
[43] J L Kelsey,et al. Reproductive factors and breast cancer. , 1993, Epidemiologic reviews.
[44] J. J. Li,et al. Hormonal Carcinogenesis , 2020, Springer New York.
[45] S. Lowry,et al. Incessant ovulation and ovarian cancer , 1991, The Lancet.
[46] K. Hall,et al. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. , 1991, Acta endocrinologica.
[47] J. Ranstam,et al. Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden. , 1989, Journal of the National Cancer Institute.
[48] K. Ebeling,et al. [Epidemiology of breast cancer]. , 1988, Archiv fur Geschwulstforschung.
[49] E. Lenton,et al. Normal variation in the length of the follicular phase of the menstrual cycle: effect of chronological age , 1984, British journal of obstetrics and gynaecology.
[50] E. Lenton,et al. Normal variation in the length of the luteal phase of the menstrual cycle: identification of the short luteal phase , 1984, British journal of obstetrics and gynaecology.
[51] H. Olsson,et al. Retrospective assessment of menstrual cycle length in patients with breast cancer, in patients with benign breast disease, and in women without breast disease. , 1983, Journal of the National Cancer Institute.